These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 37090247)

  • 1. From PERK to RIPK1: Design, synthesis and evaluation of novel potent and selective necroptosis inhibitors.
    Scarpellini C; Valembois S; Goossens K; Vadi M; Lanthier C; Klejborowska G; Van Der Veken P; De Winter H; Bertrand MJM; Augustyns K
    Front Chem; 2023; 11():1160164. PubMed ID: 37090247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. When PERK inhibitors turn out to be new potent RIPK1 inhibitors: critical issues on the specificity and use of GSK2606414 and GSK2656157.
    Rojas-Rivera D; Delvaeye T; Roelandt R; Nerinckx W; Augustyns K; Vandenabeele P; Bertrand MJM
    Cell Death Differ; 2017 Jun; 24(6):1100-1110. PubMed ID: 28452996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of novel 2,8-diazaspiro[4.5]decan-1-one derivatives as potent RIPK1 kinase inhibitors.
    Niu A; Lin L; Zhang D; Jiang K; Weng D; Zhou W; Wang J
    Bioorg Med Chem; 2022 Apr; 59():116686. PubMed ID: 35228069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of potent necroptosis inhibitors targeting RIPK1 kinase activity for the treatment of inflammatory disorder and cancer metastasis.
    Hou J; Ju J; Zhang Z; Zhao C; Li Z; Zheng J; Sheng T; Zhang H; Hu L; Yu X; Zhang W; Li Y; Wu M; Ma H; Zhang X; He S
    Cell Death Dis; 2019 Jun; 10(7):493. PubMed ID: 31235688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of the Raf kinase inhibitor TAK-632 and its analogues as potent inhibitors of necroptosis by targeting RIPK1 and RIPK3.
    Chen X; Zhuang C; Ren Y; Zhang H; Qin X; Hu L; Fu J; Miao Z; Chai Y; Liu ZG; Zhang H; Cai Z; Wang HY
    Br J Pharmacol; 2019 Jun; 176(12):2095-2108. PubMed ID: 30825190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and biological evaluation of novel cyclic malonamide derivatives as selective RIPK1 inhibitors.
    Petró JL; Bényei G; Bana P; Linke N; Horti F; Szabó JE; Szalai KK; Hornyánszky G; Greiner I; Éles J
    Bioorg Med Chem Lett; 2024 Mar; 100():129643. PubMed ID: 38316369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quizartinib inhibits necroptosis by targeting receptor-interacting serine/threonine protein kinase 1.
    Li M; Wei J; Zhu G; Fu S; He X; Hu X; Yu Y; Mou Y; Wang J; You X; Xiao X; Gu T; Ye Z; Zha Y
    FASEB J; 2023 Oct; 37(10):e23178. PubMed ID: 37698367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors Necrostatin-1 (Nec-1) and 7-Cl-O-Nec-1 (Nec-1s) are potent inhibitors of NAD(P)H: Quinone oxidoreductase 1 (NQO1).
    Yu J; Zhong B; Zhao L; Hou Y; Wang X; Chen X
    Free Radic Biol Med; 2021 Sep; 173():64-69. PubMed ID: 34252539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RIPK1-dependent cell death: a novel target of the Aurora kinase inhibitor Tozasertib (VX-680).
    Martens S; Goossens V; Devisscher L; Hofmans S; Claeys P; Vuylsteke M; Takahashi N; Augustyns K; Vandenabeele P
    Cell Death Dis; 2018 Feb; 9(2):211. PubMed ID: 29434255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of Sibiriline derivatives as novel receptor-interacting protein kinase 1 inhibitors.
    Cui N; Li S; Zhang Y; Yin F; Chen X; Luo Z; Wan S; Li X; Kong L; Wang X
    Eur J Med Chem; 2023 Mar; 250():115190. PubMed ID: 36801518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From Hit to Lead: Structure-Based Optimization of Novel Selective Inhibitors of Receptor-Interacting Protein Kinase 1 (RIPK1) for the Treatment of Inflammatory Diseases.
    Zhang L; Li Y; Tian C; Yang R; Wang Y; Xu H; Zhu Q; Chen S; Li L; Yang S
    J Med Chem; 2024 Jan; 67(1):754-773. PubMed ID: 38159286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RIPK1 can function as an inhibitor rather than an initiator of RIPK3-dependent necroptosis.
    Kearney CJ; Cullen SP; Clancy D; Martin SJ
    FEBS J; 2014 Nov; 281(21):4921-34. PubMed ID: 25195660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Receptor-interacting protein kinase 1 (RIPK1) inhibitor: a review of the patent literature (2018-present).
    Xu L; Zhang W; Zhuang C
    Expert Opin Ther Pat; 2023 Feb; 33(2):101-124. PubMed ID: 36960668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation on the chemical space of the substituted triazole thio-benzoxazepinone RIPK1 inhibitors.
    Hao Y; Shao H; Qu Z; Li J; Shi Y; Zhang W; Yu J; Fu P; Zhuang C
    Eur J Med Chem; 2022 Jun; 236():114345. PubMed ID: 35398729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery, optimization and evaluation of isothiazolo[5,4-b]pyridine derivatives as RIPK1 inhibitors with potent in vivo anti-SIRS activity.
    Hao Y; Yang C; Shu C; Li Z; Xia K; Wu S; Ma H; Tian S; Ji Y; Li J; He S; Zhang X
    Bioorg Chem; 2022 Dec; 129():106051. PubMed ID: 36115309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sibiriline, a new small chemical inhibitor of receptor-interacting protein kinase 1, prevents immune-dependent hepatitis.
    Le Cann F; Delehouzé C; Leverrier-Penna S; Filliol A; Comte A; Delalande O; Desban N; Baratte B; Gallais I; Piquet-Pellorce C; Faurez F; Bonnet M; Mettey Y; Goekjian P; Samson M; Vandenabeele P; Bach S; Dimanche-Boitrel MT
    FEBS J; 2017 Sep; 284(18):3050-3068. PubMed ID: 28715128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FKBP12 mediates necroptosis by initiating RIPK1-RIPK3-MLKL signal transduction in response to TNF receptor 1 ligation.
    Wang Z; Feng J; Yu J; Chen G
    J Cell Sci; 2019 May; 132(10):. PubMed ID: 31028177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based development of potent and selective type-II kinase inhibitors of RIPK1.
    Qin Y; Li D; Qi C; Xiang H; Meng H; Liu J; Zhou S; Gong X; Li Y; Xu G; Zu R; Xie H; Xu Y; Xu G; Zhang Z; Chen S; Pan L; Li Y; Tan L
    Acta Pharm Sin B; 2024 Jan; 14(1):319-334. PubMed ID: 38261830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RIPK1 inhibitors: A key to unlocking the potential of necroptosis in drug development.
    Bai Y; Qiao Y; Li M; Yang W; Chen H; Wu Y; Zhang H
    Eur J Med Chem; 2024 Feb; 265():116123. PubMed ID: 38199165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of RIPK1 kinase does not affect diabetes development: β-Cells survive RIPK1 activation.
    Takiishi T; Xiao P; Franchimont M; Gilglioni EH; Arroba EN; Gurzov EN; Bertrand MJ; Cardozo AK
    Mol Metab; 2023 Mar; 69():101681. PubMed ID: 36707047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.